Latest news with #clinicalTrial
Yahoo
17 hours ago
- Health
- Yahoo
Exercise may benefit colon cancer patients as much as some drugs
Exercise may significantly reduce the risk of colon cancer returning in patients after treatment, a new study has found. The late-phase trial, published Sunday in the New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, found that people who followed an exercise program after undergoing surgery and chemotherapy for Stage 3 or high-risk Stage 2 colon cancer could reduce risk of the cancer returning, a new cancer diagnosis or death by 28%. 'We approve drugs that have the same and in some cases less of a benefit than this,' said Dr. Julie Gralow, ASCO's chief medical officer. The Phase 3 randomized controlled trial included nearly 900 patients in six countries. The average age was 61 and about 90% of the participants had Stage 3 colon cancer, which recurs in about 35% of patients within five years post-treatment. The researchers followed each patient for about eight years from 2009 through 2024. After they finished surgery and chemotherapy, half of the participants were enrolled in an exercise program. The other half, the control group, was given a booklet encouraging them to exercise and eat well post-recovery. The ultimate goal of the exercise program was to get people to increase their exercise up to a certain amount each week from wherever they were starting out. That goal was a weekly increase of 10 MET hours — a unit that measures the metabolic equivalent of a task, or MET, which is the amount of energy the body uses during a task, whether it's sitting at a desk or running at full speed. How many METs a workout expends depends on how intense and how long the workout is. For reference, an hour of brisk walking is the equivalent of about 4 MET hours. The participants slowly worked up to their goal over the first six months of the program. For the first year, they met with a coach — either a physical therapist, a personal trainer or a kinesiologist — every two weeks to develop a personal exercise plan and do a supervised workout. After the first year was up, the participants met with their coach once a month for two more years. Each person's exercise plan was tailored to them. Their coaches build a regimen around what types of exercise the participants liked in the past and what types of workouts would fit into their lifestyle. 'What it translated to for most people is going on a brisk walk 45 minutes a day, four days per week,' said Dr. Christopher Booth, a medical oncologist and professor of oncology at Queen's University in Ontario, Canada. Booth, who led the trial, and his team first wanted to understand whether being assigned a coach would prompt people to exercise more after finishing cancer treatment. If so, they wanted to know whether that exercise would lower the risk of their cancer returning. The answers to both questions was yes. Eight years post-recovery, 90% of the people in the exercise program arm of the trial hadn't had a recurrence or a new cancer diagnosis, compared to 83% in the control group. Of the 445 people in the exercise group, 41 died within eight years of their cancer treatment, compared to 66 of the 444 people in the control group. People who exercised more also had a lower risk of several other cancers, including breast and other colorectal cancers. People who were not enrolled in the exercise program got between 5.2 and 7.4 fewer MET hours of exercise per week — the equivalent of 1.5 to 2.25 hours of brisk walking. 'It's not as simple as telling people to exercise,' Booth said. 'We know that for many people, getting an exercise habit is very difficult. We really need [insurers] to cover this.' The research was the first to randomize people into an exercise program who may not have otherwise exercised after cancer treatment. It builds on observational studies that have shown that people with Stage 3 colon cancer who exercise regularly live longer than those who don't. 'There is almost no downside to exercise. It should be a part of the standard treatment for colon cancer,' said Dr. Nancy You, medical director of the young onset colorectal cancer program at the University of Texas MD Anderson Cancer Center in Houston. It's still not clear why regular exercise appears to have such a large effect on colon cancer recurrence, but a growing number of studies now show that exercise can decrease the risk of breast, colon and rectal cancer recurrence, sometimes by as much as 45%. 'There are potential hypotheses related to exercise's effect on insulin, body composition and basal metabolic rate, all which can have anti-tumor effects,' said Dr. Jeffrey Meyerhardt, co-director of the Colon and Rectal Care Center at the Dana-Farber Cancer Institute in Boston. Still, it will be challenging to help patients integrate more consistent exercise into their lives after cancer, especially if they don't have access to a coach or were not very active prior to their cancer diagnosis. It's also unclear what benefit exercise would have on extending the life of someone with later-stage colon cancers, which can be incurable. 'The exciting part of this is that it really does confirm the evidence that those who exercise after their diagnosis of colon cancer can lower their risk of recurrence and increase their survival,' Meyerhardt said, adding that people should understand that exercise is an additional therapy, not a replacement for the standard care. Everyone in the trial had undergone surgery and chemotherapy prior to starting the exercise trial. For oncologists, being able to give recent cancer survivors a research-backed way to continue their recovery post-treatment is going to be an important part of patient care, Booth said. 'One of the common questions that oncologists get asked when a patient finishes chemo is, 'What else can I do, doc?' And this is really definitive. We can now say a structured exercise program done with a coach can improve your outcomes,' he said. This article was originally published on
Yahoo
18 hours ago
- Business
- Yahoo
New research presents promising findings on colorectal cancer treatment and prevention
Colorectal cancer is the second most common cause of cancer deaths in the United States, according to the American Cancer Society. This year, the organization estimates that more than 150,000 Americans will be diagnosed with it and nearly 53,000 will die from it. New studies presented at the annual meeting of the American Society of Clinical Oncology, or ASCO, in the last few days offer promising findings for both pharmaceutical and lifestyle interventions, including the impact of diet and exercise. Diagnoses of colorectal cancer have been decreasing overall for decades, the American Cancer Society says, thanks in large part to better screening. But case rates are rising among younger adults, and research estimates that colorectal cancer will become the leading cause of cancer death among adults ages 20 to 49 by 2030. Earlier research has suggested that regular exercise can improve survival rates for colorectal cancer patients, and a new study – published in the New England Journal of Medicine and presented at the ASCO conference on Sunday – confirmed those findings with robust clinical trial data. Between 2009 and 2024, researchers followed nearly 900 colon cancer patients who had completed chemotherapy – half of whom received an informational booklet that encouraged them to adopt a healthy lifestyle with good nutrition and exercise the other half of whom were also matched with a physical activity consultant for three years. They found that there was a 28% reduction in the risk of recurrence or new cancer for patients on the exercise program, with a five-year disease-free survival rate of 80% for the group with an exercise consultant compared with 74% for the group who just received the booklet. In other words, the exercise program was found to prevent 1 out of every 16 patients from developing recurrent or new cancer. 'That magnitude is comparable to – and in many cases exceeds – the magnitude of benefit offered by a lot of our very good standard cancer drugs,' said Dr. Christopher Booth, a professor of oncology with Queen's University and co-author of the new study. 'Exercise really should be considered an essential component of treatment of colon cancer.' Work is still being done to understand why exercise can help reduce the risk of cancer, but experts say that it may have something to do with the ways exercise helps reduce inflammation in the body. Another new study presented at the ASCO conference on Sunday found that anti-inflammatory diets also helped improve survival rates for people with stage 3 colon cancer. Patients who consumed more anti-inflammatory diets – including coffee, tea and vegetables such as leafy greens – and engaged in higher levels of physical activity had a 63% lower risk of death compared to patients who consumed the most inflammatory diets – including things like red meat, processed meat, refined grains and sugar-sweetened beverages – and engaged in lower levels of physical activity, the study found. 'Actively, as a field, we're learning about the role of the immune system in cancer development, and inflammation is an immune response,' said Dr. Sara Char, a clinical fellow in Hematology and Oncology at Dana-Farber Cancer Institute and lead author of the study, and the rise of colorectal cancer cases in younger people suggests it's a critical piece of the puzzle. 'When we look at the incidence of colon cancer in younger individuals … that really suggests to us that there is something in the environment – either in the foods we eat, our lifestyles, the chemicals that could be in our foods, all sorts of different things – that are outside of just genetics alone that could be driving these rates,' she said. 'So it is incredibly important for us, as a field, to be thinking about how our diet and lifestyle impacts not just our risk of developing this cancer, but then how people fare after it.' Both Booth and Char said that colorectal cancer patients are often seeking ways to proactively manage their risk. 'I think that's it's very empowering for patients,' Booth said. 'It's also achievable for patients. This is a commitment, but it's something that patients can achieve.' In his study, an 'exercise prescription' was developed based on each individual's starting point. Most people were able to reach their target increase if they went for a brisk walk for about an hour three or four days per week, Booth said. Lifestyle interventions like exercise and diet are also 'sustainable for health systems,' he said, but it's key that the system helps support patients in accessing the resources needed for behavioral interventions. Another new study showed promising results that might represent a new standard-of-care for certain patients with advanced colon cancer. On Friday, drugmaker Pfizer presented data on a colorectal cancer drug, Braftovi, used in combination with a standard chemotherapy and an antibody drug. During the trial, the drug combo was shown to double the length of time patients with an aggressive form of colorectal cancer lived with treatment: an average of 30 months compared with 15 months using currently available treatments. Braftovi targets a mutation in a specific protein that can lead to abnormal cell growth, and it's already approved by the US Food and Drug Administration to treat some forms of cancer. The study, which was funded by Pfizer, published Friday in the New England Journal of Medicine. 'It's a targeted cancer therapy that really depends on knowing what's driving patients' cancer,' Pfizer CEO Dr. Albert Bourla told CNN. These targeted therapies are one of the biggest advancements in cancer treatment over the past two decades, he said, and it's easy to diagnose whether cancer patients have the specific mutation that Braftovi can treat. The latest data on treatment for colorectal cancer a 'very, very important finding,' Bourla said, and the drugmaker plans to seek additional approval to add the new indication to the drug's label.
CNN
18 hours ago
- Business
- CNN
New research presents promising findings on colorectal cancer treatment and prevention
Colorectal cancer is the second most common cause of cancer deaths in the United States, according to the American Cancer Society. This year, the organization estimates that more than 150,000 Americans will be diagnosed with it and nearly 53,000 will die from it. New studies presented at the annual meeting of the American Society of Clinical Oncology, or ASCO, in the last few days offer promising findings for both pharmaceutical and lifestyle interventions, including the impact of diet and exercise. Diagnoses of colorectal cancer have been decreasing overall for decades, the American Cancer Society says, thanks in large part to better screening. But case rates are rising among younger adults, and research estimates that colorectal cancer will become the leading cause of cancer death among adults ages 20 to 49 by 2030. Earlier research has suggested that regular exercise can improve survival rates for colorectal cancer patients, and a new study – published in the New England Journal of Medicine and presented at the ASCO conference on Sunday – confirmed those findings with robust clinical trial data. Between 2009 and 2024, researchers followed nearly 900 colon cancer patients who had completed chemotherapy – half of whom received an informational booklet that encouraged them to adopt a healthy lifestyle with good nutrition and exercise the other half of whom were also matched with a physical activity consultant for three years. They found that there was a 28% reduction in the risk of recurrence or new cancer for patients on the exercise program, with a five-year disease-free survival rate of 80% for the group with an exercise consultant compared with 74% for the group who just received the booklet. In other words, the exercise program was found to prevent 1 out of every 16 patients from developing recurrent or new cancer. 'That magnitude is comparable to – and in many cases exceeds – the magnitude of benefit offered by a lot of our very good standard cancer drugs,' said Dr. Christopher Booth, a professor of oncology with Queen's University and co-author of the new study. 'Exercise really should be considered an essential component of treatment of colon cancer.' Work is still being done to understand why exercise can help reduce the risk of cancer, but experts say that it may have something to do with the ways exercise helps reduce inflammation in the body. Another new study presented at the ASCO conference on Sunday found that anti-inflammatory diets also helped improve survival rates for people with stage 3 colon cancer. Patients who consumed more anti-inflammatory diets – including coffee, tea and vegetables such as leafy greens – and engaged in higher levels of physical activity had a 63% lower risk of death compared to patients who consumed the most inflammatory diets – including things like red meat, processed meat, refined grains and sugar-sweetened beverages – and engaged in lower levels of physical activity, the study found. 'Actively, as a field, we're learning about the role of the immune system in cancer development, and inflammation is an immune response,' said Dr. Sara Char, a clinical fellow in Hematology and Oncology at Dana-Farber Cancer Institute and lead author of the study, and the rise of colorectal cancer cases in younger people suggests it's a critical piece of the puzzle. 'When we look at the incidence of colon cancer in younger individuals … that really suggests to us that there is something in the environment – either in the foods we eat, our lifestyles, the chemicals that could be in our foods, all sorts of different things – that are outside of just genetics alone that could be driving these rates,' she said. 'So it is incredibly important for us, as a field, to be thinking about how our diet and lifestyle impacts not just our risk of developing this cancer, but then how people fare after it.' Both Booth and Char said that colorectal cancer patients are often seeking ways to proactively manage their risk. 'I think that's it's very empowering for patients,' Booth said. 'It's also achievable for patients. This is a commitment, but it's something that patients can achieve.' In his study, an 'exercise prescription' was developed based on each individual's starting point. Most people were able to reach their target increase if they went for a brisk walk for about an hour three or four days per week, Booth said. Lifestyle interventions like exercise and diet are also 'sustainable for health systems,' he said, but it's key that the system helps support patients in accessing the resources needed for behavioral interventions. Another new study showed promising results that might represent a new standard-of-care for certain patients with advanced colon cancer. On Friday, drugmaker Pfizer presented data on a colorectal cancer drug, Braftovi, used in combination with a standard chemotherapy and an antibody drug. During the trial, the drug combo was shown to double the length of time patients with an aggressive form of colorectal cancer lived with treatment: an average of 30 months compared with 15 months using currently available treatments. Braftovi targets a mutation in a specific protein that can lead to abnormal cell growth, and it's already approved by the US Food and Drug Administration to treat some forms of cancer. The study, which was funded by Pfizer, published Friday in the New England Journal of Medicine. 'It's a targeted cancer therapy that really depends on knowing what's driving patients' cancer,' Pfizer CEO Dr. Albert Bourla told CNN. These targeted therapies are one of the biggest advancements in cancer treatment over the past two decades, he said, and it's easy to diagnose whether cancer patients have the specific mutation that Braftovi can treat. The latest data on treatment for colorectal cancer a 'very, very important finding,' Bourla said, and the drugmaker plans to seek additional approval to add the new indication to the drug's label.
Associated Press
a day ago
- Business
- Associated Press
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--May 31, 2025-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. 'The data presented today from the PANOVA-3 trial of Tumor Treating Fields show a clinically meaningful and statistically significant improvement in overall survival for people with locally advanced pancreatic cancer,' said Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial. 'Importantly, we also saw an extension in the duration of time before pain progressed. Pain is a hallmark of this disease, and as a clinician, the potential of this therapy to address this aspect of pancreatic cancer is very encouraging. These results illustrate the potential of Tumor Treating Fields therapy concomitant with gemcitabine and nab-paclitaxel to become a standard of care for unresectable, locally advanced pancreatic cancer.' The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields. 'The encouraging data from the Phase 3 PANOVA-3 study demonstrate a meaningful improvement in outcomes for patients with unresectable, locally advanced pancreatic cancer—including pain reduction and a statistically significant improvement in overall survival,' said Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. 'Pancreatic cancer remains one of the most challenging cancers to treat globally, with approximately 134,000 new cases diagnosed annually in China alone. Zai Lab participated in this trial and looks forward to continuing our collaboration with Novocure to bring this innovative therapy to patients in China as quickly as possible.' 'Most people with pancreatic cancer are diagnosed with advanced disease, which is very difficult to treat and only about 1 in 10 people are alive five years after diagnosis,' said Nicolas Leupin, MD, PhD, Chief Medical Officer, Novocure. 'The results shared today at ASCO and in the Journal of Clinical Oncology demonstrate that Tumor Treating Fields therapy improved overall survival and pain-free survival in unresectable, locally advanced pancreatic cancer. We plan to submit these data to the FDA in the second half of 2025 to support a premarket approval for Tumor Treating Fields therapy.' Results from PANOVA-3 In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement [hazard ratio (HR) 0.82; p=0.039 (N=571)]. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints including the one-year survival rate and pain-free survival. Pancreatic cancer can cause significant pain as the disease progresses and managing pain is a key clinical challenge. Quality of life was also measured as a secondary endpoint. Analyses were performed for all patients using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the pancreatic cancer specific PAN26 addendum. Deterioration-free survival in global health status, pain and digestive problems were significantly improved in patients receiving TTFields therapy concomitant with gemcitabine and nab-paclitaxel compared to the gemcitabine and nab-paclitaxel alone group. Full analysis of the quality of life results in PANOVA-3 will be shared at a future scientific conference. There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms. TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs. Data Presentation & Publication Details The PANOVA-3 data, (LBA 3500) Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC), will be presented today by Dr. Picozzi in Hall D1 during the 3:00 – 6:00 p.m. Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary oral session. The Phase 3 PANOVA-3 publication in the Journal of Clinical Oncology, Tumor Treating Fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase 3 PANOVA-3 study , will be available online at Novocure Investor Event Novocure will host an investor event featuring Dr. Picozzi and Novocure leadership after the oral presentation. Event details and a link to a live webcast of the event are available on the investor relations page of For more information or to request in-person attendance, please contact Novocure investor relations at [email protected]. Regulatory & Ongoing Clinical Study of TTFields for Pancreatic Cancer Novocure plans to file for regulatory approval for use of TTFields therapy in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3 in the U.S. in the second half of 2025. The company also plans to file for regulatory approval in EU, Japan and other key markets. Novocure continues to follow patients in its Phase 2 PANOVA-4 trial exploring the use of TTFields therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment with data anticipated in the first half of 2026. About PANOVA-3 PANOVA-3 is an international prospective, randomized, open-label, controlled Phase 3 clinical trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields) therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment for locally advanced pancreatic adenocarcinoma. Patients were randomized to receive either TTFields therapy concomitant with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity. The PANOVA-3 trial enrolled 571 patients who were randomized 1:1 and followed for a minimum of 18 months. About PANOVA-4 PANOVA-4 is an international, multi-center, Phase 2 clinical trial designed to test the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. The primary endpoint is disease control rate. Secondary endpoints include overall survival, progression-free survival, one-year survival rate, objective response rate, progression-free survival at six months, duration of response, and toxicity. The study is designed to enroll 76 patients and enrollment is complete. About Pancreatic Cancer in China Pancreatic cancer is one of the most common and deadliest cancers globally. In China, there were an estimated 134,374 new cases in 2022, and it is now the eighth most common cancer type 1. The current median survival of patients with locally advanced, unresectable pancreatic cancer is nine to twelve months, and the five-year survival rate was 7.2% 2, making it the malignancy with the lowest survival rate in China. 1 Xia C, Dong X, Li H et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135: 584-590. 2 Hu JX, Zhao CF, Chen WB et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol 2021; 27: 4298-4321. About Tumor Treating Fields Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit About Zai Lab Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at , About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter. Zai Lab Forward-Looking Statements This press release contains forward-looking statements about future expectations, plans, and prospects for Zai Lab, including, without limitation, statements regarding the prospects of and plans for developing and commercializing TTFields therapy, the potential benefits of TTFields therapy, and the potential treatment of pancreatic cancer. These forward-looking statements may contain words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would,' and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at View source version on CONTACT: For more information, please contact: Zai Lab Investor Relations: Christine Chiou / Lina Zhang +1 (917) 886-6929 / +86 136 8257 6943 [email protected]/[email protected] Zai Lab Media: Shaun Maccoun / Xiaoyu Chen +1 (857) 270-8854 / +86 185 0015 5011 [email protected]/[email protected] Novocure Investors: Ingrid Goldberg [email protected] Novocure Media: Catherine Falcetti [email protected] KEYWORD: ILLINOIS MASSACHUSETTS SWITZERLAND CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC EUROPE INDUSTRY KEYWORD: RESEARCH FDA CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH SCIENCE ONCOLOGY SOURCE: Zai Lab Limited Copyright Business Wire 2025. PUB: 05/31/2025 03:08 PM/DISC: 05/31/2025 03:07 PM
Yahoo
2 days ago
- Business
- Yahoo
BioLineRx upgraded to Buy from Hold at JonesResearch
JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot phase data from the investigator-initiated Phase II combination trial of motixafortide plus PD-1 inhibitor cemiplimab plus chemo in first line pancreatic cancer where seven of 11 patients responded to therapy and 10 of 11 achieved disease control, the analyst tells investors in a research note. With these results, the firm believes BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial assuming favorable Phase II results. It sees potential for more favorable stock momentum first line pancreatic cancer 'in play.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on BLRX: Disclaimer & DisclosureReport an Issue BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial BioLineRx announces new data from Phase 2 combination trial of motixafortide BioLineRx ADR: Positive Earnings Call Highlights and Challenges BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating BioLineRx Ltd. Reports Q1 2025 Financial Results Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
